Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

Biraja C. Dash; Hassan Peyvandi; Kaiti Duan; Edward Richardson; Sifon U. Ndon; Kyle S. Gabrick; Athena A. Faz; John A. Persing; Alan Dardik; Henry C. Hsia

LAPSE

Living Archive for Process Systems Engineering

LAPSE:2021.0409

Published Article

LAPSE:2021.0409

Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)

Biraja C. Dash, Hassan Peyvandi, Kaiti Duan, Edward Richardson, Sifon U. Ndon, Kyle S. Gabrick, Athena A. Faz, John A. Persing, Alan Dardik, Henry C. Hsia

May 25, 2021

Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. Based on pathological findings, TAO can be considered as a distinct form of vasculitis that is most prevalent in young male smokers. There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. Surgical bypass has limited utility and 24% of patients will ultimately require amputation. Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. In this review, we summarize the current knowledge of TAO treatment and provide an overview of stem cell-based treatment modalities.

Record ID

LAPSE:2021.0409

Keywords

angiogenesis, immunomodulation, inflammation, mesenchymal stem cell, pluripotent stem cell, thromboangiitis obliterans

Subject

Biosystems

Suggested Citation

C. Dash B, Peyvandi H, Duan K, Richardson E, U. Ndon S, S. Gabrick K, A. Faz A, A. Persing J, Dardik A, C. Hsia H. Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease). (2021). LAPSE:2021.0409

Author Affiliations

C. Dash B: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA [ORCID]
Peyvandi H: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
Duan K: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
Richardson E: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
U. Ndon S: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
S. Gabrick K: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
A. Faz A: Hearing Disorders Research Center, Loghman Hakim Medical Center, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran
A. Persing J: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA
Dardik A: Vascular Biology and Therapeutics Program and The Department of Surgery, Yale School of Medicine, Yale University, New Haven, CT 06519, USA [ORCID]
C. Hsia H: Department of Surgery, Section of Plastic Surgery, Yale University School of Medicine, PO Box 208041, New Haven, CT 06520-8041, USA

Journal Name

Processes

Volume

8

Issue

11

Article Number

E1408

Year

2020

Publication Date

2020-11-04